Craig C. Hopkinson, EVP R&D, Chief Medical Officer at Alkermes plc. (ALKS), sold 698,680 shares at $32.69 ($23.7M) on 2025-02-12, disclosed to the SEC on 2025-02-14.
Scheduled sale ($23.7M) by EVP R&D, Chief Medical Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $32.69 | 171,813 | $5.6M | 23.7% |
| 2 | $32.69 | 171,813 | $5.6M | 23.7% |
| 3 | $33.27 | 33,108 | $1.1M | 4.6% |
| 4 | $33.27 | 33,108 | $1.1M | 4.6% |
| 5 | $34.02 | 35,586 | $1.2M | 5.1% |
| 6 | $34.02 | 35,586 |
| $1.2M |
| 5.1% |
| 7 | $36.02 | 108,833 | $3.9M | 16.5% |
| 8 | $36.02 | 108,833 | $3.9M | 16.5% |
| Total | $33.92 avg | 698,680 | $23.7M | 100% |
| Filing → |
| ALKS | SELL | 2026-07-01 | $464K | — | Filing → |
| ALKS | SELL | 2026-06-01 | $375K | — | Filing → |
| ALKS | SELL | 2026-05-01 | $301K | — | Filing → |